AI assistant
Dechra Pharmaceuticals PLC — Share Issue/Capital Change 2019
Sep 16, 2019
4797_rns_2019-09-16_9773a21b-38bb-4081-bb43-4c5e516314c8.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4823M
Dechra Pharmaceuticals PLC
16 September 2019
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 16 September 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Long-Term Incentive Scheme | |||
| Period of return: | From: | 15 March 2019 | To: | 14 September 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 6,415 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 138,129 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 5,857 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 138,687 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 16 September 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Approved Share Option Scheme | |||
| Period of return: | From: | 15 March 2019 | To: | 14 September 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 12,836 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 8,328 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 8,561 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 12,603 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 16 September 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Unapproved Share Option Scheme | |||
| Period of return: | From: | 15 March 2019 | To: | 14 September 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 114,238 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 26,140 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 38,568 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 101,810 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to a ris.
Date: 16 September 2019
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | SAYE Scheme | |||
| Period of return: | From: | 15 March 2019 | To: | 14 September 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 56,121 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 30,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 20,779 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 65,342 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRLLFLVASIRLIA